A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2011
08/10/2011	EP2354124A2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
08/10/2011	EP2354120A1 Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
08/10/2011	EP2353614A1 Methods and immune modulatory nucleic acid compositions for preventing and treating disease
08/10/2011	EP2353606A2 Compositions and methods for the treatment of CNS injuries
08/10/2011	EP2353601A1 Uronic acid and probiotics
08/10/2011	EP2353599A1 8-hydroxyquinolines as inhibitors of cathepsin B
08/10/2011	EP2353598A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain
08/10/2011	EP2353597A1 Arene chromium-carbonyl complexes, method for their preparation of and use thereof as pharmaceuticals
08/10/2011	EP2353596A1 Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
08/10/2011	EP2353595A1 Nutritional compensation for western-type diet
08/10/2011	EP2353594A1 Compositions comprising tramadol and the co-crystal of celecoxib and L-proline in the treatment of pain
08/10/2011	EP2353593A1 Non-nucleoside reverse transcriptase inhibitors
08/10/2011	EP2353592A1 Therapeutic causing contraction of mucosal tissue and method of treating diseases relating to mucosal tissues
08/10/2011	EP2353591A1 Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
08/10/2011	EP2353587A2 Antimicrobial compositions and methods
08/10/2011	EP2352837A1 Novel polyamino polyketide antibiotics and uses thereof
08/10/2011	EP2352829A1 Treating hepatitis c virus infection with over-expression of microrna-196
08/10/2011	EP2352743A2 Modulation of toll-like receptor 5 expression by antisense oligonucleotides
08/10/2011	EP2352734A1 Tricyclic nitrogen compounds used as antibacterials
08/10/2011	EP2352733A1 Benzonaphtyridine compounds used as inhibitors of autotaxin
08/10/2011	EP2352732A1 2, 5-diamino-substituted pyrido ý4, 3-d¨pyrimidines as autotaxin inhibitors against cancer
08/10/2011	EP2352731A1 Gamma secretase modulators
08/10/2011	EP2352730A2 Biologically active amides
08/10/2011	EP2352729A1 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
08/10/2011	EP2352727A1 Trpv1 antagonists
08/10/2011	EP2352726A1 Trpv1 antagonists
08/10/2011	EP2352725A1 Quinoxaline-based lxr modulators
08/10/2011	EP2352724A2 Aryl guanidine f1f0-atpase inhibitors and related methods
08/10/2011	EP2352723A2 Halogen-substituted compounds used as pesticides
08/10/2011	EP2352722A2 Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
08/10/2011	EP2352568A1 Administration of an adsorbent polymer for treatment of systemic inflammation
08/10/2011	EP2352522A1 Bispecific intracellular delivery vehicles
08/10/2011	EP2352510A1 Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
08/10/2011	EP2352505A2 D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
08/10/2011	EP2352504A2 Treatment of proliferative disorders with a death receptor agonist
08/10/2011	EP2352503A1 Role of soluble upar in the pathogenesis of proteinuric kidney disease
08/10/2011	EP2352502A2 Limited proteolysis of cd2ap and progression of renal disease
08/10/2011	EP2352501A1 Compounds for the treatment of osteoporosis and cancers
08/10/2011	EP2352500A1 Method of inducing negative chemotaxis
08/10/2011	EP2352499A1 Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
08/10/2011	EP2352498A1 Compositions and methods for minimizing or reversing agonist-induced desensitization
08/10/2011	EP2352497A2 Compositions containing delta-9-thc-amino acid esters and process of preparation
08/10/2011	EP2352496A1 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
08/10/2011	EP2352495A1 Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
08/10/2011	EP2352494A1 Novel and potent tapentadol dosage forms
08/10/2011	EP2352493A1 Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
08/10/2011	EP2352492A2 Small molecule modulators of epigenetic regulation and their therapeutic applications
08/10/2011	EP2352488A1 Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
08/10/2011	EP2352487A1 Combination of lycopene, polyphenol, and vitamins for the care of keratin material
08/10/2011	EP2352486A1 Skin whitener
08/10/2011	EP2352374A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
08/10/2011	EP2352373A1 Triazole beta carboline derivatives as antidiabetic compounds
08/10/2011	EP2265580B1 Novel method for the production of sulphonylpyrroles as hdac inhibitors
08/10/2011	EP2247593B1 Pyrrolopyrazine kinase inhibitors
08/10/2011	EP2203431B1 Anti-infective pyrimidines and uses thereof
08/10/2011	EP2197854B1 A new class of histone deacetylase inhibitors
08/10/2011	EP2190815B1 Pyrrolidine aryl-ether as nk3 receptor antagonists
08/10/2011	EP2170873B1 Isoxazole-imidazole derivatives
08/10/2011	EP2163548B1 Prophylactic or therapeutic agent for age-related macular degeneration
08/10/2011	EP2137167B1 Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
08/10/2011	EP1973524B1 Concentrated liquid thyroid hormone composition
08/10/2011	EP1968574B1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
08/10/2011	EP1948603B1 Tetrahydroindole derivatives for treatment of alzheimer's disease
08/10/2011	EP1928840B1 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
08/10/2011	EP1896405B1 Organic compounds
08/10/2011	EP1841760B1 Pyrimidine derivatives as kinase modulators and method of use
08/10/2011	EP1836177B1 Vitamin d receptor modulators
08/10/2011	EP1830853B1 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
08/10/2011	EP1814895B1 Apparatus and system having dry control gene silencing compositions
08/10/2011	EP1802641B1 Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
08/10/2011	EP1761551B1 Gemcitabine derivatives nanoparticles
08/10/2011	EP1751163B1 Benzazepine compounds having affinity for dopamine d3 receptor and uses thereof
08/10/2011	EP1675591B1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
08/10/2011	EP1663225B1 Compositions for veterinary and medical applications
08/10/2011	EP1656126B1 Preparing method for controlled released type tablet comprising tamsulosin hcl and the tablet produced thereof
08/10/2011	EP1643864B1 Aiding of cognitive function
08/10/2011	EP1637152B1 A notoginseng saponin intravenous injection and the method for preparing this injection
08/10/2011	EP1626971B1 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
08/10/2011	EP1609781B1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine
08/10/2011	EP1602377B1 Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition
08/10/2011	EP1594513B1 Carbohydrate conjugates to prevent abuse of controlled substances
08/10/2011	EP1565581B1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
08/10/2011	EP1507554B1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
08/10/2011	EP1430157B1 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/10/2011	EP1421069B1 Process for the preparation of cyclopenta[g]quinazoline derivatives
08/10/2011	EP1383465B1 Acute pharmacologic augmentation of psychotherapy with d-cycloserine
08/10/2011	EP1341527B1 Pharmaceutical preparation comprising an active dispersed on a matrix
08/10/2011	EP1296986B1 5-aminoalkyl-pyrazolo[ 4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect
08/10/2011	EP1135513B2 Adenovirus-mediated gene therapy
08/10/2011	DE202011004859U1 Arznei- oder Nahrungsergänzungsmittel zur Behandlung und/oder Beschleunigung der Regeneration nach Erkrankungen und/oder nach Leistungsspitzen Medicinal or dietary supplement for the treatment and / or accelerating the recovery from disease and / or after power peaks
08/10/2011	CN201921301U 护心养心理疗带 Cardiac care psychological therapy with dependents
08/10/2011	CN1985988B Novel medicine composition for treating hepatic diseases
08/10/2011	CN1980937B Thienopyridone carboxamides and their medical use
08/10/2011	CN1972940B Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists
08/10/2011	CN1938276B Crystalline pyrazoles
08/10/2011	CN1919250B Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease
08/10/2011	CN1919234B Application of pharmaceutical composition in the process of preparing medicine for preventing and treating plateau cardiac muscle hypoxidosis
08/10/2011	CN1919223B Medicinal composition of notoginsen triterpenes and notoginsenoside
08/10/2011	CN1910167B Selective estrogen receptor modulators for the treatment of vasomotor symptoms
08/10/2011	CN1898237B Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

1 ... 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 ... 7860